Top

Published in:

Open Access 30-05-2023 | Celiac Disease | IM - REVIEW

Gut inflammation and tumorigenesis: every site has a different tale to tell

Authors: Alessandro Vanoli, Paola Parente, Matteo Fassan, Luca Mastracci, Federica Grillo

Published in: Internal and Emergency Medicine | Issue 8/2023

Abstract

Gut inflammation has been correlated with cancerogenesis by disrupting gastrointestinal homeostasis. Numerous chronic inflammatory disorders of the tubular gastrointestinal tract (e.g., gastroesophageal reflux disease, Helicobacter pylori-induced and autoimmune chronic gastritis, celiac disease, and inflammatory bowel diseases) have been variably associated with an increased neoplastic risk. Gastrointestinal inflammation-induced neoplasms include epithelial tumors (esophageal squamous cell carcinoma and adenocarcinoma, gastric adenocarcinoma and neuroendocrine tumors, small bowel adenocarcinoma and neuroendocrine tumors, and colorectal cancer) and lymphomas (such as gastric marginal zone lymphomas and enteropathy-associated T cell lymphoma). In the last decades, numerous studies have investigated the pathogenetic mechanisms and the microenvironmental/microbiome changes that trigger genetic and/or epigenetic alterations eventually leading to tumorigenesis, often through a histologically recognizable inflammation-dysplasia-carcinoma cancerogenic sequence. In the present review, an overview of the current knowledge on the links between inflammatory diseases and neoplasms of the tubular GI tract, applying a site-by-site approach, is provided.

Wen Y, Zhu Y, Zhang C, Yang X, Gao Y, Li M, Yang H, Liu T, Tang H (2022) Chronic inflammation, cancer development and immunotherapy. Front Pharmacol 13:1040163. https://doi.org/10.3389/fphar.2022.1040163CrossRefPubMedPubMedCentral

Tambunting L, Kelleher D, Duggan SP (2022) The Immune Underpinnings of Barrett’s-associated adenocarcinogenesis: a retrial of nefarious immunologic co-conspirators. Cell Mol Gastroenterol Hepatol 13:1297–1315. https://doi.org/10.1016/j.jcmgh.2022.01.023CrossRefPubMedPubMedCentral

D’Souza SM, Houston K, Keenan L, Yoo BS, Parekh PJ, Johnson DA (2021) Role of microbial dysbiosis in the pathogenesis of esophageal mucosal disease: a paradigm shift from acid to bacteria? World J Gastroenterol 27:2054–2072. https://doi.org/10.3748/wjg.v27.i18.2054CrossRefPubMedPubMedCentral

Chela HK, Gangu K, Ertugrul H, Juboori AA, Daglilar E, Tahan V (2022) The 8th Wonder of the Cancer World: esophageal cancer and inflammation. Diseases 10:44. https://doi.org/10.3390/diseases10030044CrossRefPubMedPubMedCentral

Prabhu A, Obi KO, Rubenstein JH (2014) The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol 109:822–827. https://doi.org/10.1038/ajg.2014.71CrossRefPubMed

Gonçalves RB, Coletta RD, Silvério KG, Benevides L, Casati MZ, da Silva JS, Nociti FH Jr (2011) Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm Res 60:409–424. https://doi.org/10.1007/s00011-011-0308-7CrossRefPubMed

Fiocca R, Mastracci L, Milione M, Parente P, Savarino V; Gruppo Italiano Patologi Apparato Digerente (GIPAD), Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP) (2011) Microscopic esophagitis and Barrett's esophagus: the histology report. Dig Liver Dis 43(Suppl 4):S319–S330. https://doi.org/10.1016/S1590-8658(11)60588-4

Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ (2009) Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 137:1776–1784. https://doi.org/10.1053/j.gastro.2009.07.055CrossRefPubMed

Dunbar KB, Agoston AT, Odze RD, Huo X, Pham TH, Cipher DJ, Castell DO, Genta RM, Souza RF, Spechler SJ (2016) Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA 315:2104–2112. https://doi.org/10.1001/jama.2016.5657CrossRefPubMedPubMedCentral

10.

Mastracci L, Bruzzone M, Pacella E, Tinelli C, Zentilin P, Savarino E, De Silvestri A, Fiocca R, Grillo F (2016) The contribution of intraepithelial inflammatory cells to the histological diagnosis of microscopic esophagitis. Esophagus 13:80–87. https://doi.org/10.1007/s10388-015-0501-9CrossRef

11.

Ustaoglu A, Nguyen A, Spechler S, Sifrim D, Souza R, Woodland P (2020) Mucosal pathogenesis in gastro-esophageal reflux disease. Neurogastroenterol Motil 32:e14022. https://doi.org/10.1111/nmo.14022

12.

Abdel-Latif MM, Duggan S, Reynolds JV, Kelleher D (2009) Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol 9:396–404. https://doi.org/10.1016/j.coph.2009.06.010CrossRefPubMed

13.

Moons LM, Kusters JG, Bultman E, Kuipers EJ, van Dekken H, Tra WM, Kleinjan A, Kwekkeboom J, van Vliet AH, Siersema PD (2005) Barrett’s oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol 207:269–276. https://doi.org/10.1002/path.1847CrossRefPubMed

14.

Kavanagh ME, Conroy MJ, Clarke NE, Gilmartin NT, O’Sullivan KE, Feighery R, MacCarthy F, O’Toole D, Ravi N, Reynolds JV, O’Sullivan J, Lysaght JV (2016) Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma. Cancer Lett 370:117–124. https://doi.org/10.1016/j.canlet.2015.10.019CrossRefPubMed

15.

Lagisetty KH, McEwen DP, Nancarrow DJ, Schiebel JG, Ferrer-Torres D, Ray D, Frankel TL, Lin J, Chang AC, Kresty LA, Beer DG (2021) Immune determinants of Barrett's progression to esophageal adenocarcinoma. JCI Insight 6:e143888. https://doi.org/10.1172/jci.insight.143888

16.

Sundaram S, Kim EN, Jones GM, Sivagnanam S, Tripathi M, Miremadi A, Di Pietro M, Coussens LM, Fitzgerald RC, Chang YH, Zhuang L (2022) Deciphering the immune complexity in esophageal adenocarcinoma and pre-cancerous lesions with sequential multiplex immunohistochemistry and sparse subspace clustering approach. Front Immunol 13:874255. https://doi.org/10.3389/fimmu.2022.874255

17.

Sharma T, Gupta A, Chauhan R, Bhat AA, Nisar S, Hashem S, Akhtar S, Ahmad A, Haris M, Singh M, Uddin S (2022) Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis. Cancer Metastasis Rev 41:281–299. https://doi.org/10.1007/s10555-022-10026-6CrossRefPubMedPubMedCentral

18.

Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, Faculty members of Kyoto Global Consensus Conference (2015) Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64:1353–1367. https://doi.org/10.1136/gutjnl-2015-309252

19.

Rugge M, Genta RM, Di Mario F, El-Omar EM, El-Serag HB, Fassan M, Hunt RH, Kuipers EJ, Malfertheiner P, Sugano K, Graham DY (2017) Gastric cancer as preventable disease. Clin Gastroenterol Hepatol 15:1833–1843. https://doi.org/10.1016/j.cgh.2017.05.023CrossRefPubMed

20.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Personal habits and indoor combustions: volume 100 E—a review of human carcinogens (2012) IARC monographs on the evaluation of carcinogenic risks to humans/World Health Organization. Int Agency Res Cancer 100:1–538

21.

Wang F, Meng W, Wang B, Qiao L (2014) Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 34:196–202. https://doi.org/10.1016/j.canlet.2013.08.016CrossRef

22.

Businello G, Angerilli V, Parente P, Realdon S, Savarino E, Farinati F, Grillo F, Vanoli A, Galuppini F, Paccagnella S, Pennelli G, Mastracci L, Saragoni L, Fassan M (2021) Molecular landscapes of gastric pre-neoplastic and pre-invasive lesions. Int J Mol Sci 22:9950. https://doi.org/10.3390/ijms22189950CrossRefPubMedPubMedCentral

23.

Angerilli V, Pennelli G, Galuppini F, Realdon S, Fantin A, Savarino E, Farinati F, Mastracci L, Luchini C, Fassan M (2022) Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA/ACRG classes. Virchows Arch 481:545–552. https://doi.org/10.1007/s00428-022-03392-7CrossRefPubMedPubMedCentral

24.

Fassan M, Brignola S, Pennelli G, Alberti G, Angerilli V, Bressan A, Pellino A, Lanza C, Salmaso R, Lonardi S, Pucciarelli S, Spolverato G, Scarpa M, Realdon S, Farinati F, Luchini C, Rugge M, Loupakis F (2020) PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Arch 477:151–156. https://doi.org/10.1007/s00428-019-02693-8CrossRefPubMed

25.

Chen XZ, Chen H, Castro FA, Hu JK, Brenner H (2015) Epstein–Barr virus infection and gastric cancer: a systematic review. Medicine (Baltimore) 94:e792. https://doi.org/10.1097/MD.0000000000000792

26.

Pennelli G, Grillo F, Galuppini F, Ingravallo G, Pilozzi E, Rugge M, Fiocca R, Fassan M, Mastracci L (2020) Gastritis: update on etiological features and histological practical approach. Pathologica 112:153–165. https://doi.org/10.32074/1591-951X-163

27.

Bergman MP, D’Elios MM (2010). Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma. J Biomed Biotechnol 2010:104918. https://doi.org/10.1155/2010/104918

28.

Lenti MV, Rugge M, Lahner E, Miceli E, Toh BH, Genta RM, De Block C, Hershko C, Di Sabatino A (2020) Autoimmune gastritis. Nat Rev Dis Primers 6:56. https://doi.org/10.1038/s41572-020-0187-8CrossRefPubMed

29.

Rugge M, Bricca L, Guzzinati S, Sacchi D, Pizzi M, Savarino E, Farinati F, Zorzi M, Fassan M, Dei Tos AP, Malfertheiner P, Genta RM, Graham DY (2022) Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients. Gut. https://doi.org/10.1136/gutjnl-2022-327827 (epub ahead of print)

30.

Pizzi M, Sabattini E, Parente P, Bellan A, Doglioni C, Lazzi S (2020) Gastrointestinal lymphoproliferative lesions: a practical diagnostic approach. Pathologica 112:227–247. https://doi.org/10.32074/1591-951X-161

31.

Raderer M, Kiesewetter B (2021) What you always wanted to know about gastric MALT- lymphoma: a focus on recent developments. Ther Adv Med Oncol 13:17588359211033824. https://doi.org/10.1177/17588359211033825CrossRefPubMedPubMedCentral

32.

Violeta Filip P, Cuciureanu D, Sorina Diaconu L, Maria Vladareanu A, Silvia Pop C (2018) MALT lymphoma: epidemiology, clinical diagnosis and treatment. J Med Life 11:187–193. https://doi.org/10.25122/jml-2018-0035

33.

Giuffrida P, Vanoli A, Arpa G, Bonometti A, Luinetti O, Solcia E, Corazza GR, Paulli M, Di Sabatino A (2018) Small bowel carcinomas associated with immune-mediated intestinal disorders: the current knowledge. Cancers (Basel) 11:31. https://doi.org/10.3390/cancers11010031CrossRefPubMed

34.

Yu J, Refsum E, Perrin V, Helsingen LM, Wieszczy P, Løberg M, Bretthauer M, Adami HO, Ye W, Blom J, Kalager M (2022) Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel. Ann Oncol 33:649–656. https://doi.org/10.1016/j.annonc.2022.02.226CrossRefPubMed

35.

Svrcek M, Piton G, Cosnes J, Beaugerie L, Vermeire S, Geboes K, Lemoine A, Cervera P, El-Murr N, Dumont S, Scriva A, Lascols O, Ardizzone S, Fociani P, Savoye G, Le Pessot F, Novacek G, Wrba F, Colombel JF, Leteurtre E, Bouhnik Y, Cazals-Hatem D, Cadiot G, Diebold MD, Rahier JF, Delos M, Fléjou JF, Carbonnel F (2014) Small bowel adenocarcinomas complicating Crohn’s disease are associated with dysplasia: a pathological and molecular study. Inflamm Bowel Dis 20:1584–1592. https://doi.org/10.1097/MIB.0000000000000112CrossRefPubMed

36.

Vanoli A, Di Sabatino A, Martino M, Klersy C, Grillo F, Mescoli C, Nesi G, Volta U, Fornino D, Luinetti O, Fociani P, Villanacci V, D’Armiento FP, Cannizzaro R, Latella G, Ciacci C, Biancone L, Paulli M, Sessa F, Rugge M, Fiocca R, Corazza GR, Solcia E (2017) Small bowel carcinomas in celiac or Crohn’s disease: distinctive histophenotypic, molecular and histogenetic patterns. Mod Pathol 30:1453–1466. https://doi.org/10.1038/modpathol.2017.40CrossRefPubMed

37.

Arpa G, Vanoli A, Grillo F, Fiocca R, Klersy C, Furlan D, Sessa F, Ardizzone S, Sampietro G, Macciomei MC, Nesi G, Tonelli F, Capella C, Latella G, Ciardi A, Caronna R, Lenti MV, Ciccocioppo R, Barresi V, Malvi D, D’Errico A, Rizzello F, Poggioli G, Mescoli C, Rugge M, Luinetti O, Paulli M, Di Sabatino A, Solcia E (2021) Prognostic relevance and putative histogenetic role of cytokeratin 7 and MUC5AC expression in Crohn’s disease-associated small bowel carcinoma. Virchows Arch 479:667–678. https://doi.org/10.1007/s00428-021-03109-2CrossRefPubMedPubMedCentral

38.

Piton G, Cosnes J, Monnet E, Beaugerie L, Seksik P, Savoye G, Cadiot G, Flourie B, Capelle P, Marteau P, Lemann M, Colombel JF, Khouri E, Bonaz B, Carbonnel F (2008) Risk factors associated with small bowel adenocarcinoma in Crohn’s disease: a case-control study. Am J Gastroenterol 103:1730–1736. https://doi.org/10.1111/j.1572-0241.2008.01847.xCrossRefPubMed

39.

Liao X, Li G, McBride R, Houldsworth J, Harpaz N, Polydorides AD (2020) Clinicopathological and molecular characterisation of Crohn’s Disease-associated small bowel adenocarcinomas. J Crohns Colitis 14:287–294. https://doi.org/10.1093/ecco-jcc/jjz135

40.

Aparicio T, Svrcek M, Henriques J, Afchain P, Lièvre A, Tougeron D, Gagniere J, Terrebonne E, Piessen G, Legoux JL, Lecaille C, Pocard M, Gornet JM, Zaanan A, Lavau-Denes S, Lecomte T, Deutsch D, Vernerey D, Puig PL (2021) Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort. Int J Cancer 148:1731–1742. https://doi.org/10.1002/ijc.33392CrossRefPubMed

41.

Wan Q, Zhao R, Xia L, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu XT (2021) Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies. J Cancer Res Clin Oncol 147:1077–1087. https://doi.org/10.1007/s00432-020-03496-0CrossRefPubMed

42.

Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV Jr (2013) Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 19:1384–1389. https://doi.org/10.1097/MIB.0b013e318281325eCrossRefPubMed

43.

Vitale G, Dicitore A, Barrea L, Sbardella E, Razzore P, Campione S, Faggiano A, Colao A; NIKE, Albertelli M, Altieri B, Bottiglieri F, De Cicco F, Di Molfetta S, Fanciulli G, Feola T, Ferone D, Ferraù F, Gallo M, Giannetta E, Grillo F, Grossrubatscher E, Guadagno E, Guarnotta V, Isidori AM, Lania A, Lenzi A, Calzo FL, Malandrino P, Messina E, Modica R, Muscogiuri G, Pes L, Pizza G, Pofi R, Puliani G, Rainone C, Rizza L, Rubino M, Ruggieri RM, Sesti F, Venneri MA, Zatelli MC (2021) From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: are we on the highway to hell? Rev Endocr Metab Disord 22:511–525. https://doi.org/10.1007/s11154-020-09589-y

44.

Massironi S, Rossi RE, Milanetto AC, Andreasi V, Campana D, Nappo G, Partelli S, Gallo C, Scaravaglio M, Zerbi A, Panzuto F, Pasquali C, Falconi M, Invernizzi P, On Behalf Of ItaNet Italian Association For Neuroendocrine Tumours Study Group (2022) Duodenal gastric metaplasia and duodenal neuroendocrine neoplasms: more than a simple coincidence? J Clin Med 11:2658. https://doi.org/10.3390/jcm11092658

45.

Matsubara A, Ogawa R, Suzuki H, Oda I, Taniguchi H, Kanai Y, Kushima R, Sekine S (2015) Activating GNAS and KRAS mutations in gastric foveolar metaplasia, gastric heterotopia, and adenocarcinoma of the duodenum. Br J Cancer 112:1398–1404. https://doi.org/10.1038/bjc.2015.104CrossRefPubMedPubMedCentral

46.

Elfström P, Granath F, Ekström Smedby K, Montgomery SM, Askling J, Ekbom A, Ludvigsson JF (2011) Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. J Natl Cancer Inst 103:436–444. https://doi.org/10.1093/jnci/djq564CrossRefPubMed

47.

Marafini I, Monteleone G, Stolfi C (2020) Association between Celiac Disease and cancer. Int J Mol Sci 21:4155. https://doi.org/10.3390/ijms21114155CrossRefPubMedPubMedCentral

48.

Lebwohl B, Green PHR, Emilsson L, Mårild K, Söderling J, Roelstraete B, Ludvigsson JF (2022) Cancer risk in 47,241 individuals with celiac disease: a Nationwide Cohort Study. Clin Gastroenterol Hepatol 20:e111–e131. https://doi.org/10.1016/j.cgh.2021.05.034CrossRefPubMed

49.

Han Y, Chen W, Li P, Ye J (2015) Association between Coeliac Disease and risk of any malignancy and gastrointestinal malignancy: a meta-analysis. Medicine (Baltimore) 94:e1612. https://doi.org/10.1097/MD.0000000000001612

50.

Emilsson L, Semrad C, Lebwohl B, Green PHR, Ludvigsson JF (2020) Risk of small bowel adenocarcinoma, adenomas, and carcinoids in a Nationwide Cohort of Individuals with Celiac Disease. Gastroenterology 159:1686-1694.e2. https://doi.org/10.1053/j.gastro.2020.07.007CrossRefPubMed

51.

Potter DD, Murray JA, Donohue JH, Burgart LJ, Nagorney DM, van Heerden JA, Plevak MF, Zinsmeister AR, Thibodeau SN (2004) The role of defective mismatch repair in small bowel adenocarcinoma in celiac disease. Cancer Res 64(19):7073–7077. https://doi.org/10.1158/0008-5472.CAN-04-1096CrossRefPubMed

52.

Vanoli A, Di Sabatino A, Furlan D, Klersy C, Grillo F, Fiocca R, Mescoli C, Rugge M, Nesi G, Fociani P, Sampietro G, Ardizzone S, Luinetti O, Calabrò A, Tonelli F, Volta U, Santini D, Caio G, Giuffrida P, Elli L, Ferrero S, Latella G, Ciardi A, Caronna R, Solina G, Rizzo A, Ciacci C, D’Armiento FP, Salemme M, Villanacci V, Cannizzaro R, Canzonieri V, Reggiani Bonetti L, Biancone L, Monteleone G, Orlandi A, Santeusanio G, Macciomei MC, D’Incà R, Perfetti V, Sandri G, Silano M, Florena AM, Giannone AG, Papi C, Coppola L, Usai P, Maccioni A, Astegiano M, Migliora P, Manca R, Martino M, Trapani D, Cerutti R, Alberizzi P, Riboni R, Sessa F, Paulli M, Solcia E, Corazza GR (2017) Small bowel carcinomas in coeliac or Crohn’s Disease: clinico-pathological, molecular, and prognostic features. A study from the Small Bowel Cancer Italian Consortium. J Crohns Colitis 11:942–953. https://doi.org/10.1093/ecco-jcc/jjx031CrossRefPubMed

53.

Soderquist CR, Bhagat G (2021) Cellular and molecular bases of refractory celiac disease. Int Rev Cell Mol Biol 358:207–240. https://doi.org/10.1016/bs.ircmb.2020.12.001CrossRefPubMed

54.

Lenti MV, Biagi F, Lucioni M, Di Sabatino A, Paulli M, Corazza GR (2019) Two cases of monomorphic epitheliotropic intestinal T-cell lymphoma associated with coeliac disease. Scand J Gastroenterol 54:965–968. https://doi.org/10.1080/00365521.2019.1647455CrossRefPubMed

55.

Pelizzaro F, Marsilio I, Fassan M, Piazza F, Barberio B, D’Odorico A, Savarino EV, Farinati F, Zingone F (2021) The risk of malignancies in celiac disease—a literature review. Cancers (Basel) 13:5288. https://doi.org/10.3390/cancers13215288CrossRefPubMed

56.

Ciccocioppo R, Croci GA, Biagi F, Vanoli A, Alvisi C, Cavenaghi G, Riboni R, Arra M, Gobbi PG, Paulli M, Corazza GR (2018) Intestinal T-cell lymphoma with enteropathy-associated T-cell lymphoma-like features arising in the setting of adult autoimmune enteropathy. Hematol Oncol 36:481–488. https://doi.org/10.1002/hon.2494CrossRefPubMed

57.

Washington K, Stenzel TT, Buckley RH, Gottfried MR (1996) Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Pathol 20:1240–1252. https://doi.org/10.1097/00000478-199610000-00010CrossRefPubMed

58.

Leone P, Vacca A, Dammacco F, Racanelli V (2018) Common variable immunodeficiency and gastric malignancies. Int J Mol Sci 19:451. https://doi.org/10.3390/ijms19020451CrossRefPubMedPubMedCentral

59.

Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10:639–645. https://doi.org/10.1016/j.cgh.2012.01.010CrossRefPubMed

60.

Olén O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, Ekbom A, Sørensen HT, Ludvigsson JF (2020) Colorectal cancer in Crohn’s disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol 5:475–484. https://doi.org/10.1016/S2468-1253(20)30005-4CrossRefPubMed

61.

Remo A, Fassan M, Vanoli A, Bonetti LR, Barresi V, Tatangelo F, Gafà R, Giordano G, Pancione M, Grillo F, Mastracci L (2019) Morphology and molecular features of rare colorectal carcinoma histotypes. Cancers (Basel) 11:1036. https://doi.org/10.3390/cancers11071036CrossRefPubMed

62.

Nagao-Kitamoto H, Kitamoto S, Kamada N (2022) Inflammatory bowel disease and carcinogenesis. Cancer Metastasis Rev 41:301–316. https://doi.org/10.1007/s10555-022-10028-4CrossRefPubMed

63.

Porter RJ, Arends MJ, Churchhouse AMD, Din S (2021) Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines. J Crohns Colitis 15:2131–2141. https://doi.org/10.1093/ecco-jcc/jjab102CrossRefPubMedPubMedCentral

64.

Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC et al (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14:931–968. https://doi.org/10.1016/s0046-8177(83)80175-0CrossRefPubMed

65.

Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R, SCENIC Guideline Development Panel (2015) SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 81:489–501.e26. https://doi.org/10.1016/j.gie.2014.12.009

66.

Lee H, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT (2021) Non-conventional dysplasia in inflammatory bowel disease is more frequently associated with advanced neoplasia and aneuploidy than conventional dysplasia. Histopathology 78:814–830. https://doi.org/10.1111/his.14298CrossRefPubMed

67.

Choi WT, Yozu M, Miller GC, Shih AR, Kumarasinghe P, Misdraji J, Harpaz N, Lauwers GY (2020) Nonconventional dysplasia in patients with inflammatory bowel disease and colorectal carcinoma: a multicenter clinicopathologic study. Mod Pathol 33:933–943. https://doi.org/10.1038/s41379-019-0419-1CrossRefPubMed

68.

Nguyen ED, Wang D, Lauwers GY, Choi WT (2022) Increased histologic inflammation is an independent risk factor for nonconventional dysplasia in ulcerative colitis. Histopathology 81:644–652. https://doi.org/10.1111/his.14765CrossRefPubMed

69.

Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526–535. https://doi.org/10.1136/gut.48.4.526CrossRefPubMedPubMedCentral

70.

Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M (2012) Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143:375–81.e1. https://doi.org/10.1053/j.gastro.2012.04.016 (quiz e13–4)

71.

Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:45145–45149. https://doi.org/10.1053/j.gastro.2003.11.010CrossRef

72.

Faye AS, Holmer AK, Axelrad JE (2022) Cancer in inflammatory bowel disease. Gastroenterol Clin North Am 51:649–666. https://doi.org/10.1016/j.gtc.2022.05.003CrossRefPubMed

73.

Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sassaki L (2022) Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol 28:4053–4060. https://doi.org/10.3748/wjg.v28.i30.4053CrossRefPubMedPubMedCentral

Title: Gut inflammation and tumorigenesis: every site has a different tale to tell
Authors: Alessandro Vanoli
Paola Parente
Matteo Fassan
Luca Mastracci
Federica Grillo
Publication date: 30-05-2023
Publisher: Springer International Publishing
Keywords: Celiac Disease
Celiac Disease
Gastritis
Helicobacter Pylori
Chronic Inflammatory Bowel Disease
Gastroesophageal Reflux Disease
Lymphoma
Esophagitis
Colorectal Cancer
Colorectal Cancer
Barrett Esophagus
Published in: Internal and Emergency Medicine / Issue 8/2023
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-023-03320-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2023

A European national health and social service model: imagining a rational philosophy for health care organizations

Impact of a sepsis tracking sheet and emergency department pharmacists on sepsis compliance measures: a prospective emergency department analysis

Estimated plasma volume status adds prognostic value to hemodynamic parameters in advanced heart failure

The measurement of the left ventricle ejection fraction by a bedside FoCUS examination

Head-to-head comparison of six warning scores to predict mortality and clinical impairment in COVID-19 patients in emergency department

Correction: Raising the curtain: from the gut lumen to human health and disease—the point of interest for internal medicine

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials